世界卫生组织胰胆管细胞病理学报告系统:与PSC系统的比较综述
世界卫生组织(WHO)联合国际细胞学会和国际癌症研究机构推出胰胆管细胞病理学报告系统(WHO系统),将原PSC系统的6级分类修订为7级。该系统将良性肿瘤归入「良性」类别,取消「肿瘤:良性」类别,并将低度恶性肿瘤、PanNET和SPN归为「恶性」,同时新增PaN-Low和PaN-High两个诊断类别,并纳入各分类恶性肿瘤风险及资源分层管理选项。
要点
- WHO系统采用7级分类:不足/不满意/无诊断、良性、非典型、PaN-Low、PaN-High、可疑恶性、恶性。
- 低度恶性肿瘤、PanNET和SPN从PSC的「肿瘤:其他」改归为「恶性」。
- WHO系统保留影像学关联和辅助检测(CEA、淀粉酶、分子检测)的建议。
核心结论
- WHO系统将PSC系统的6级分类修订为7级,并重新定义了良性和恶性类别。
- WHO系统纳入各分类的恶性肿瘤风险及适应中低收入国家资源差异的报告和管理选项。
研究设计与样本
- 本文为综述,基于WHO系统和PSC系统两份报告文件进行解释和比较。
主要发现
- WHO系统的诊断类别包括「不足/不满意/无诊断」、「良性(恶性阴性)」、「非典型」、「胰胆管肿瘤低风险/低级别(PaN-Low)」、「胰腺肿瘤高风险/高级别(PaN-High)」、「可疑恶性」和「恶性」。
- WHO系统的「良性」类别同时包括非肿瘤性和肿瘤性病变,因此PSC系统的「肿瘤:良性」类别被取消。
- 低度恶性肿瘤、胰腺神经内分泌肿瘤(PanNETs)和实性假乳头状肿瘤(SPN)在PSC系统中归为「肿瘤:其他」,在WHO系统中归为「恶性」。
- WHO系统的「肿瘤」类别仅保留导管内病变,并分为「PaN-Low」和「PaN-High」两个新诊断类别。
- 与PSC系统一样,WHO系统提倡与影像学密切关联,并鼓励将辅助检测(如生化检测CEA和淀粉酶、分子检测)纳入最终诊断。
关键数值与推荐
- WHO系统采用7级分类,PSC系统为6级分类。
- WHO系统将PSC系统的「肿瘤:良性」类别取消,良性类别涵盖非肿瘤性和肿瘤性病变。
- 低度恶性肿瘤、PanNETs和SPN在WHO系统中归为「恶性」,在PSC系统中归为「肿瘤:其他」。
- 导管内病变在WHO系统中分为PaN-Low和PaN-High两个类别。
- WHO系统纳入各分类的恶性肿瘤风险,并提供适应低中收入国家资源差异的报告和管理选项。
临床怎么用
- 病理科医生应按照WHO系统的7级分类进行胰胆管细胞病理学报告。
- 报告时应结合影像学,并酌情纳入CEA、淀粉酶等生化检测及分子检测辅助诊断。
- 可根据各分类的恶性肿瘤风险及当地资源选择相应的诊断管理选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: The World Health Organization (WHO) Reporting System for Pancreaticobiliary Cytopathology (WHO System) is the product of a joint venture between the World Health Organization, the International Academy of Cytology, and the International Agency for Research on Cancer. The WHO System revises the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology (PSC System) and replaces the 6-tiered system with a 7-tiered system. OBJECTIVE.—: To explain the WHO System and the differences with the PSC System. DATA SOURCES.—: The WHO System and the PSC System of Reporting Pancreaticobiliary Cytopathology. CONCLUSIONS.—: The diagnostic categories of the WHO System are "Insufficient/Inadequate/Nondiagnostic"; "Benign (Negative for Malignancy)"; "Atypical"; "Pancreaticobiliary Neoplasm, Low Risk/Low Grade (PaN-Low)"; "Pancreatic Neoplasm, High Risk/High Grade (PaN-High)"; "Suspicious for Malignancy"; and "Malignant." In the WHO System, the "benign" category includes both nonneoplastic and neoplastic lesions, so the "Neoplastic: Benign" category of the PSC system has been eliminated. Low-grade malignancies, pancreatic neuroendocrine tumors (PanNETs), and solid-pseudopapillary neoplasm (SPN) classified as "Neoplastic: Other" in the PSC System are classified as "Malignant" in the WHO System, leaving in the "Neoplasm" category intraductal lesions, which are divided into 2 new diagnostic categories: "Pancreaticobiliary Neoplasm (PaN)-Low Risk/Grade" and "PaN-High Risk/Grade." As with the PSC System, the WHO System advocates close correlation with imaging and encourages incorporation of ancillary testing into the final diagnosis, such as biochemical (carcinoembryonic antigen [CEA] and amylase) and molecular testing. The WHO System includes risk of malignancy per category, and reporting and diagnostic management options that recognize the variations in resources of low- and middle-income countries.
引用
- Pitman MB. The World Health Organization Reporting System for Pancreaticobiliary Cytopathology: Review and Comparison to the Papanicolaou Society of Cytopathology System. Arch Pathol Lab Med. 2025. PMID: 38190275. doi:10.5858/arpa.2023-0411-RA
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。